Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,376.56
(
-0.86%
)
News Focus
News Focus
Post# of 257579
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 118752

Saturday, 04/23/2011 6:07:11 PM

Saturday, April 23, 2011 6:07:11 PM

Post# of 257579
ABT’s 44% YoY growth in ex-US sales of drug-eluting stents (#msg-62371726) is an impressive stat insofar the growth was entirely organic. Rapid uptake of Xience in Japan was a major contributor.

ABT’s DES sales in 1Q11 include Xience, Xience Prime, and the profit share ABT gets from BSX on Promus (which has now ended).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today